NBIX Stock Overview
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders.
No risks detected for NBIX from our risk checks.
Neurocrine Biosciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$75.10|
|52 Week High||US$120.27|
|52 Week Low||US$71.88|
|1 Month Change||-11.74%|
|3 Month Change||-26.77%|
|1 Year Change||-35.76%|
|3 Year Change||-16.89%|
|5 Year Change||86.08%|
|Change since IPO||500.80%|
Recent News & Updates
Here's Why I Think Neurocrine Biosciences (NASDAQ:NBIX) Might Deserve Your Attention Today
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Stay On Top Of Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Neurocrine Biosciences: Generic Drug Stock Seen As Underpriced By Market-Makers For Near Gains
Sharp down days are when to look for surprise values in underpriced stocks. Not the story issues being ballyhooed by touts and the media - everyone knows them. The hidden values are ones found by experienced professional researchers who know the details of industry group issues and their special strengths. They know when to add them to their institutional employer’s multi-billion-$ portfolio. That’s when sudden forced Market-Maker liquidity requires price protection by hedging. For investor portfolios where wealth-building is a principal objective, this is the place to find near-term capital gain reliability.
|NBIX||US Biotechs||US Market|
Return vs Industry: NBIX underperformed the US Biotechs industry which returned -22% over the past year.
Return vs Market: NBIX underperformed the US Market which returned 4.2% over the past year.
|NBIX Average Weekly Movement||5.6%|
|Biotechs Industry Average Movement||10.2%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: NBIX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: NBIX's weekly volatility (6%) has been stable over the past year.
About the Company
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company’s portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia.
Neurocrine Biosciences Fundamentals Summary
|NBIX fundamental statistics|
Is NBIX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NBIX income statement (TTM)|
|Cost of Revenue||US$320.50m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Feb 11, 2022
|Earnings per share (EPS)||4.69|
|Net Profit Margin||41.59%|
How did NBIX perform over the long term?See historical performance and comparison
Is Neurocrine Biosciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NBIX ($75.1) is trading below our estimate of fair value ($351.07)
Significantly Below Fair Value: NBIX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NBIX is good value based on its PE Ratio (16x) compared to the US Biotechs industry average (23.1x).
PE vs Market: NBIX is good value based on its PE Ratio (16x) compared to the US market (16.5x).
Price to Earnings Growth Ratio
PEG Ratio: NBIX is good value based on its PEG Ratio (0.5x)
Price to Book Ratio
PB vs Industry: NBIX is overvalued based on its PB Ratio (5.3x) compared to the US Biotechs industry average (1.9x).
How is Neurocrine Biosciences forecast to perform in the next 1 to 3 years based on estimates from 22 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NBIX's forecast earnings growth (31.2% per year) is above the savings rate (2%).
Earnings vs Market: NBIX's earnings (31.2% per year) are forecast to grow faster than the US market (13% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: NBIX's revenue (16.8% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: NBIX's revenue (16.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NBIX's Return on Equity is forecast to be high in 3 years time (22.5%)
How has Neurocrine Biosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NBIX has high quality earnings.
Growing Profit Margin: NBIX's current net profit margins (41.6%) are higher than last year (9%).
Past Earnings Growth Analysis
Earnings Trend: NBIX has become profitable over the past 5 years, growing earnings by 77.6% per year.
Accelerating Growth: NBIX's earnings growth over the past year (376.2%) exceeds its 5-year average (77.6% per year).
Earnings vs Industry: NBIX earnings growth over the past year (376.2%) exceeded the Biotechs industry 11%.
Return on Equity
High ROE: NBIX's Return on Equity (33%) is considered high.
How is Neurocrine Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: NBIX's short term assets ($1.0B) exceed its short term liabilities ($225.9M).
Long Term Liabilities: NBIX's short term assets ($1.0B) exceed its long term liabilities ($445.4M).
Debt to Equity History and Analysis
Debt Level: NBIX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if NBIX's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: NBIX's debt is well covered by operating cash flow (104.9%).
Interest Coverage: NBIX's interest payments on its debt are well covered by EBIT (9.7x coverage).
What is Neurocrine Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NBIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NBIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NBIX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NBIX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NBIX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kevin Gorman (63 yo)
Dr. Kevin C. Gorman, Ph D., has been the President and Chief Executive Officer of Neurocrine Biosciences, Inc. since January 2008. Dr. Gorman is a Founder of Neurocrine Biosciences, Inc. Dr. Gorman was Exe...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD13.88M) is above average for companies of similar size in the US market ($USD6.49M).
Compensation vs Earnings: Kevin's compensation has increased by more than 20% in the past year.
Experienced Management: NBIX's management team is seasoned and experienced (6.7 years average tenure).
Experienced Board: NBIX's board of directors are seasoned and experienced ( 11.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Neurocrine Biosciences, Inc.'s employee growth, exchange listings and data sources
- Name: Neurocrine Biosciences, Inc.
- Ticker: NBIX
- Exchange: NasdaqGS
- Founded: 1992
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$7.124b
- Shares outstanding: 94.87m
- Website: https://www.neurocrine.com
Number of Employees
- Neurocrine Biosciences, Inc.
- 12780 El Camino Real
- San Diego
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/23 23:18|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.